{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:17:19Z","timestamp":1777792639281,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00198-014-2944-6","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T14:40:06Z","timestamp":1417531206000},"page":"699-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial"],"prefix":"10.1007","volume":"26","author":[{"given":"H. G.","family":"Bone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. W.","family":"Dempster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Eisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. L.","family":"Greenspan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. J.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rybak-Feiglin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Santora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Verbruggen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. T.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,29]]},"reference":[{"key":"2944_CR1","doi-asserted-by":"crossref","unstructured":"Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285; 1: 785-95","DOI":"10.1001\/jama.285.6.785"},{"key":"2944_CR2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229\u2013238","journal-title":"J Bone Miner Res"},{"key":"2944_CR3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","volume":"11","author":"TJ Martin","year":"2005","unstructured":"Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76\u201381","journal-title":"Trends Mol Med"},{"key":"2944_CR4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nm.1979","volume":"15","author":"Y Tang","year":"2009","unstructured":"Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, Feng X, Van Hul W, Wan M, Cao X (2009) TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15:757\u2013765","journal-title":"Nat Med"},{"key":"2944_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","volume":"4","author":"C Zhao","year":"2006","unstructured":"Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K (2006) Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111\u2013121","journal-title":"Cell Metab"},{"issue":"1","key":"2944_CR6","first-page":"666","volume":"123","author":"S Lotinun","year":"2013","unstructured":"Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E, Horne WC, Baron R (2013) Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 123(1):666\u2013681","journal-title":"J Clin Invest"},{"issue":"1","key":"2944_CR7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(1):337\u2013342","journal-title":"Nature"},{"issue":"5","key":"2944_CR8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(5):677\u2013692","journal-title":"Bone"},{"issue":"1","key":"2944_CR9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1359\/jbmr.1997.12.8.1143","volume":"12","author":"RP Heaney","year":"1997","unstructured":"Heaney RP, Yates AJ, Santora AC (1997) Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 12(1):1143\u20131151","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2944_CR10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S8756-3282(01)00613-5","volume":"29","author":"CJ Hernandez","year":"2001","unstructured":"Hernandez CJ, Beaupre GS, Marcus R, Carter DR (2001) A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 29(1):511\u2013516","journal-title":"Bone"},{"issue":"2","key":"2944_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","volume":"29","author":"P Roschger","year":"2001","unstructured":"Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29(2):185\u2013191","journal-title":"Bone"},{"issue":"2","key":"2944_CR12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","volume":"59","author":"RM Zebaze","year":"2014","unstructured":"Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E (2014) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59(2):173\u2013179","journal-title":"Bone"},{"issue":"1","key":"2944_CR13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrrheum.2011.130","volume":"7","author":"EM Lewiecki","year":"2011","unstructured":"Lewiecki EM (2011) New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 7(1):631\u2013638","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2944_CR14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrrheum.2011.77","volume":"7","author":"AG Costa","year":"2011","unstructured":"Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 7(1):447\u2013456","journal-title":"Nat Rev Rheumatol"},{"key":"2944_CR15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","volume":"273","author":"BD Gelb","year":"1996","unstructured":"Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236\u20131238","journal-title":"Science"},{"key":"2944_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bonekey.2012.67","volume":"1","author":"L Duong","year":"2012","unstructured":"Duong L (2012) Therapeutic inhibition of cathepsin K\u2014reducing bone resorption while maintaining bone formation. BoneKEy Rep 1:1\u20138","journal-title":"BoneKEy Rep"},{"key":"2944_CR17","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1359\/jbmr.2001.16.8.1444","volume":"16","author":"R Kiviranta","year":"2001","unstructured":"Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J (2001) Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 16:1444\u20131452","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2944_CR18","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1021\/jm0504961","volume":"48","author":"JP Falgueyret","year":"2005","unstructured":"Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, Lamontagne S, Masse F, Riendeau D, Toulmond S, Percival MD (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 48(2):7535\u20137543","journal-title":"J Med Chem"},{"key":"2944_CR19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","volume":"18","author":"JY Gauthier","year":"2008","unstructured":"Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Leger S, LeRiche T, Li CS, Masse F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Therien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923\u2013928","journal-title":"Bioorg Med Chem Lett"},{"key":"2944_CR20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2009.60","volume":"86","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86:175\u2013182","journal-title":"Clin Pharmacol Ther"},{"key":"2944_CR21","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2125.2012.04471.x","volume":"75","author":"SA Stoch","year":"2013","unstructured":"Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, Liu L, Scott BB, Panebianco D, Ding Y, Gottesdiener K, Wagner JA (2013) Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics\u2014results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol 75:1240\u20131254","journal-title":"Br J Clin Pharmacol"},{"key":"2944_CR22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","volume":"25","author":"HG Bone","year":"2010","unstructured":"Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937\u2013947","journal-title":"J Bone Miner Res"},{"key":"2944_CR23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242\u2013251","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2944_CR24","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","volume":"27","author":"B Langdahl","year":"2012","unstructured":"Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez PJ, Denker A, Lombardi A, Le Bailly DT, DaSilva C, Rosenberg E, Leung A (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27(1):2251\u20132258","journal-title":"J Bone Miner Res"},{"issue":"24","key":"2944_CR25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1359\/jbmr.2003.18.6.1133","volume":"18","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Alexandre JM, Bone HG, Abadie E, Brasseur D, Chassany O, Durrleman S, Lekkerkerker JF, Caulin F (2003) Study design in osteoporosis: a European perspective. J Bone Miner Res 18(24):1133\u20131138","journal-title":"J Bone Miner Res"},{"key":"2944_CR26","unstructured":"Clinical trials for new osteoporosis treatments 2002. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/cder02 htm#EndocrinologicMetabolicDrugs"},{"key":"2944_CR27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"2944_CR28","unstructured":"Study to evaluate the safety and efficacy of BA058 for prevention of fracture in postmenopausal women 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01343004?term=BA-058&rank=3"},{"key":"2944_CR29","unstructured":"Multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of AMG 785 treatment in postmenopausal women with osteoporosis 2012. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01575834?term=AMG+785&rank=13A"},{"issue":"2","key":"2944_CR30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(2):1137\u20131148","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2944_CR31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.bone.2011.07.017","volume":"49","author":"RR Recker","year":"2011","unstructured":"Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB (2011) Issues in modern bone histomorphometry. Bone 49(1):955\u2013964","journal-title":"Bone"},{"issue":"2","key":"2944_CR32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(2):2\u201317","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2944_CR33","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O\u2019Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(1):2267\u20132294","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2944_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O\u2019Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1\u201323","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2944_CR35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","volume":"4","author":"O Miettinen","year":"1985","unstructured":"Miettinen O, Nurminen M (1985) Comparative analysis of two rates. Stat Med 4(2):213\u2013226, 13","journal-title":"Stat Med"},{"key":"2944_CR36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57:289\u2013300","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"2944_CR37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","volume":"75","author":"YA Hochberg","year":"1988","unstructured":"Hochberg YA (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrica 75:800\u2013802","journal-title":"Biometrica"},{"key":"2944_CR38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"2944_CR39","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","volume":"366","author":"DM Black","year":"2012","unstructured":"Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long? N Engl J Med 366:2051\u20132053","journal-title":"N Engl J Med"},{"issue":"1","key":"2944_CR40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(1):1189\u20131199","journal-title":"N Engl J Med"},{"issue":"1","key":"2944_CR41","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/sim.3870","volume":"29","author":"E Vittinghoff","year":"2010","unstructured":"Vittinghoff E, McCulloch CE, Woo C, Cummings SR (2010) Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med 29(1):1127\u20131136","journal-title":"Stat Med"},{"issue":"1","key":"2944_CR42","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellstrom D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98(1):4483\u20134492","journal-title":"J Clin Endocrinol Metab"}],"updated-by":[{"DOI":"10.1007\/s00198-015-3274-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T00:00:00Z","timestamp":1441843200000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-014-2944-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2944-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2944-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T14:30:15Z","timestamp":1717597815000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-014-2944-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,29]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["2944"],"URL":"https:\/\/doi.org\/10.1007\/s00198-014-2944-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,29]]}}}